<PAGE> 1
Page 1 of 4 Pages
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 10)*
North American Vaccine, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
657-201-109
- --------------------------------------------------------------------------------
(CUSIP Number)
Charles-A. Tessier, Vice-President, Legal Affairs and General Counsel
BioChem Pharma Inc., 275 Armand Frappier Boulevard,
Laval, Quebec H7V 4A7 Canada
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
August 11, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
SCHEDULE 13D
CUSIP NO. 657-201-109 Page 2 of 4 pages
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BIOCHEM PHARMA INC.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Laval, Quebec, Canada
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 15,040,704
BENEFICIALLY ----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING N/A
PERSON ----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
15,040,704
----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
N/A
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,040,704
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
N/A
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
41.6%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
Page 3 of 4 Pages
This amendment Number 10 amends and supplements the Statement on Schedule
13D (the "Schedule 13D") filed on behalf of BioChem Pharma Inc. ("BioChem"), a
publicly-owned Canadian pharmaceutical company incorporated under the laws of
Canada, relating to the common stock, no par value per share, of North American
Vaccine, Inc. (the "Company"). Capitalized terms used and not defined in this
Amendment have the meanings set forth in the Schedule 13D. Item 4 of the
Schedule 13D, "Purpose of Transaction", is hereby amended and supplemented to
add the following:
Item 4. Purpose of Transaction
On August 4, 1999, BioChem signed an engagement letter which appointed
Salomon Smith Barney Canada Inc. as its financial advisor in connection with a
potential transaction with respect to the Company. Such potential transaction
could include the sale of all or a portion of the securities issued by the
Company which are currently held by BioChem, the purchase of all or a portion
of the outstanding equity securities issued by the Company which are not
currently held by BioChem or other strategic transactions involving the Company.
On August 11, 1999, BioChem and the Company entered into a confidentiality
agreement (the "Confidentiality Agreement") in order to gain access to
information in the possession of the Company which BioChem desires to evaluate
in order to determine its future plans with respect to its holdings of
securities issued by the Company. Under the terms of the Confidentiality
Agreement, BioChem has agreed to hold confidential all information received
from the Company and to refrain from engaging in certain actions.
BioChem is currently considering a number of plans and proposals which may
result in one or more actions described in subparagraphs (a) through (j) of
Schedule 13D. BioChem reserves the right to determine in the future whether to
pursue any plans or proposals of the type specified above.
<PAGE> 4
Page 4 of 4 Pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BIOCHEM PHARMA INC.
By: /s/ Charles-A. Tessier
-----------------------------
Charles-A. Tessier
Vice-President, Legal Affairs
and General Counsel
Dated: August 12, 1999
